CardioCovidV1, Main, Corpus, bibRecord, 000149

Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.

Identifieur interne : 000149 ( Main/Corpus ); précédent : 000148; suivant : 000150

Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.

Auteurs : Praveen Sharma ; Ashish Kumar

Source :

Diabetes & metabolic syndrome [ 1878-0334 ] ; 2020.

RBID : pubmed:32540736

Abstract

BACKGROUND AND AIMS

Liver involvement is common in COVID-19. Elevated aspartate and alanine amino transaminase (AST/ALT) and borderline increase in serum bilirubin and serum alkaline phosphatase (ALP) are the commonest findings. Patients with associated co morbid conditions like obesity, cardiovascular disease, renal disease, malignancy, hypertension and old age are prone to develop severe disease. Limited data is available in patients with COVID-19 and metabolic dysfunction associated fatty liver disease (MAFLD).The aim of this review is to analyse the effect of MAFLD on severity of COVID-19.

METHODS

We systematically searched the PubMed database till May 20, 2020 and retrieved all the articles published on COVID-19 and fatty liver/MAFLD/NAFLD.

RESULTS

Limited studies done had shown four to six fold high risk of severe COVID-19 in patients with MAFLD. Patients with MAFLD and associated obesity, severe fibrosis and age <60 yrs are more prone to develop severe COVID-19.

CONCLUSION

MAFLD is associated with 4-6 fold increase in severity of COVID-19 compared to non MAFLD patients. Physician and hepatologist should follow these patients cautiously and preventive measures to be taken strictly in these high risk patients.

DOI: 10.1016/j.dsx.2020.06.013
PubMed: 32540736

Links to Exploration step

pubmed:32540736

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.</title>
<author><name sortKey="Sharma, Praveen" sort="Sharma, Praveen" uniqKey="Sharma P" first="Praveen" last="Sharma">Praveen Sharma</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India. Electronic address: drpraveen_sharma@yahoo.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Ashish" sort="Kumar, Ashish" uniqKey="Kumar A" first="Ashish" last="Kumar">Ashish Kumar</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32540736</idno>
<idno type="pmid">32540736</idno>
<idno type="doi">10.1016/j.dsx.2020.06.013</idno>
<idno type="wicri:Area/Main/Corpus">000149</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000149</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.</title>
<author><name sortKey="Sharma, Praveen" sort="Sharma, Praveen" uniqKey="Sharma P" first="Praveen" last="Sharma">Praveen Sharma</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India. Electronic address: drpraveen_sharma@yahoo.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Ashish" sort="Kumar, Ashish" uniqKey="Kumar A" first="Ashish" last="Kumar">Ashish Kumar</name>
<affiliation><nlm:affiliation>Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Diabetes & metabolic syndrome</title>
<idno type="eISSN">1878-0334</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND AIMS</b>
</p>
<p>Liver involvement is common in COVID-19. Elevated aspartate and alanine amino transaminase (AST/ALT) and borderline increase in serum bilirubin and serum alkaline phosphatase (ALP) are the commonest findings. Patients with associated co morbid conditions like obesity, cardiovascular disease, renal disease, malignancy, hypertension and old age are prone to develop severe disease. Limited data is available in patients with COVID-19 and metabolic dysfunction associated fatty liver disease (MAFLD).The aim of this review is to analyse the effect of MAFLD on severity of COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We systematically searched the PubMed database till May 20, 2020 and retrieved all the articles published on COVID-19 and fatty liver/MAFLD/NAFLD.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Limited studies done had shown four to six fold high risk of severe COVID-19 in patients with MAFLD. Patients with MAFLD and associated obesity, severe fibrosis and age <60 yrs are more prone to develop severe COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>MAFLD is associated with 4-6 fold increase in severity of COVID-19 compared to non MAFLD patients. Physician and hepatologist should follow these patients cautiously and preventive measures to be taken strictly in these high risk patients.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32540736</PMID>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0334</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>Jun</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Diabetes & metabolic syndrome</Title>
<ISOAbbreviation>Diabetes Metab Syndr</ISOAbbreviation>
</Journal>
<ArticleTitle>Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.</ArticleTitle>
<Pagination><MedlinePgn>825-827</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1871-4021(20)30182-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dsx.2020.06.013</ELocationID>
<Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Liver involvement is common in COVID-19. Elevated aspartate and alanine amino transaminase (AST/ALT) and borderline increase in serum bilirubin and serum alkaline phosphatase (ALP) are the commonest findings. Patients with associated co morbid conditions like obesity, cardiovascular disease, renal disease, malignancy, hypertension and old age are prone to develop severe disease. Limited data is available in patients with COVID-19 and metabolic dysfunction associated fatty liver disease (MAFLD).The aim of this review is to analyse the effect of MAFLD on severity of COVID-19.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched the PubMed database till May 20, 2020 and retrieved all the articles published on COVID-19 and fatty liver/MAFLD/NAFLD.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Limited studies done had shown four to six fold high risk of severe COVID-19 in patients with MAFLD. Patients with MAFLD and associated obesity, severe fibrosis and age <60 yrs are more prone to develop severe COVID-19.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MAFLD is associated with 4-6 fold increase in severity of COVID-19 compared to non MAFLD patients. Physician and hepatologist should follow these patients cautiously and preventive measures to be taken strictly in these high risk patients.</AbstractText>
<CopyrightInformation>Copyright © 2020. Published by Elsevier Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName>
<ForeName>Praveen</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India. Electronic address: drpraveen_sharma@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kumar</LastName>
<ForeName>Ashish</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Diabetes Metab Syndr</MedlineTA>
<NlmUniqueID>101462250</NlmUniqueID>
<ISSNLinking>1871-4021</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CoiStatement>Declaration of competing interest None.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32540736</ArticleId>
<ArticleId IdType="pii">S1871-4021(20)30182-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.dsx.2020.06.013</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000149 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CardioCovidV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32540736
   |texte=   Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32540736" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CardioCovidV1

This area was generated with Dilib version V0.6.35.
Data generation: Tue Aug 4 15:08:30 2020. Site generation: Wed Jan 27 11:23:02 2021

	Serveur d'exploration Covid et maladies cardiovasculaires
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Covid et maladies cardiovasculaires

Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.

Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki